Navigation Links
Insmed to Appeal Delisting Notification From Nasdaq
Date:12/26/2007

RICHMOND, Va., Dec. 26 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has requested a hearing before a Nasdaq Listing Qualifications Panel to appeal an earlier Staff Determination to delist the Company's common stock from the Nasdaq Global Market.

Insmed received a letter from the Nasdaq Stock Market ("Nasdaq") on December 20, 2007 indicating that the Company has failed to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share for continued listing of the Company's common stock on the Nasdaq Global Market as set forth in Marketplace Rule 4450(a)(5) (the "Staff Determination"). As a result, the Company's common stock is subject to be delisted from the Nasdaq Global Market on December 31, 2007. Following procedures set forth in the Nasdaq Marketplace Rule 4800 series, Insmed has requested a hearing before a Nasdaq Listing Qualifications Panel (the "Panel") to review the Staff Determination. The hearing request will stay the delisting of the Company's common stock, pending the decision of the Panel, allowing it to continue to trade on the Nasdaq Global Market. There can be no assurance however, that the Panel will grant Insmed's request for continued listing on the Nasdaq Global Market.

In the event that the Panel denies the Company's request for continued listing on the Nasdaq Global Market, the Company's common stock could be eligible to trade on the Nasdaq Capital Market or the OTC Bulletin Board.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursua
'/>"/>

SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
4. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
5. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
6. Biomira Inc. receives Nasdaq delisting notification
7. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
8. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
9. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... May 12 /PRNewswire/ - Cytochroma today announced that ... Chief Financial Officer (CFO).,Mr. Wieland, 63, brings to ... financial management, at both public and private companies, ... "Rich has strong leadership skills, extensive experience managing,finance ...
... Lasers that emit ultrashort pulses of light are ... eye surgery, spectroscopy and controlling chemical reactions. But ... distortions caused by lenses and other optical components ... , To better understand the distortions, researchers at ...
... On Diagnostic Products and Target Validation, ... announced today,that SomaLogic and Otsuka Pharmaceutical Co., ... SomaLogic,s proprietary aptamer technology,to discover and develop ... that will enhance Otsuka,s pharmaceutical discovery and ...
Cached Biology Technology:Cytochroma Appoints R. Richard Wieland II As CFO 2New technique measures ultrashort laser pulses at focus 2New technique measures ultrashort laser pulses at focus 3SomaLogic and Otsuka Enter Into Research Collaboration 2SomaLogic and Otsuka Enter Into Research Collaboration 3
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... led by a Michigan State University professor has discovered a link ... one of the disease,s most common and potentially blindness-causing complications. ... vessels in the retina that affects up to 80 percent of ... to the nerves found in bone marrow that leads to the ...
... beetle, a pest that feasts on corn roots and corn ... the U.S., also can survive on the perennial grass ... likely be grown alongside corn, researchers report. Rootworm beetle ... and adult beetles will lay their eggs at the base ...
... COLD SPRING HARBOR, N.Y. (Jan. 5, 2010) ... proteomics have dramatically increased the need for quantitative reasoning ... the most routine informatics tools rely on statistical assumptions ... scientific results are to be correct, understood, and exploited ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Miscanthus, a biofuels crop, can host western corn rootworm 2Miscanthus, a biofuels crop, can host western corn rootworm 3New handbook for biologists who need more competence or confidence in statistics 2
... DALTsix Gradient Maker, 1. Modular system ... 2-D electrophoresis.Run up to six lab-cast ... cm) simultaneously.Use with 18- or 24-cm ... pre-assembled hinged gel cassettes.Innovative design simplifies ...
Mycoplasma Removal Agent (MRA) has been developed for cell culture, to combat the widespread problems caused by contamination of cell cultures with mycoplasma....
albumin from bovine serum (BSA), 2,4-dinitrophenylated (DNP-BSA)...
Request Info...
Biology Products: